Skip to content

17-108 - A Study to Assess the Effects of Bempedoic Acid in Patients with or at high risk for Cardiovascular Disease

Status: open

A Randomized, Double-Blind, Placebo-Controlled study to Assess the Effects of Bempedoic Acid (ETC-1002) on the occurrence of Major Cardiovascular Events in Patients with, or at High Risk for Cardiovascular Disease who are Statin-Intolerant

Treatment for Cardiovascular Disease

Contact Us Or call 251-471-7027


The primary objective is to evaluate whether administration of bempedoic acid 180 mg/day versus placebo reduces the risk of MACE in patients with, or at high risk for, CVD who are statin intolerant. This will be assessed with a composite primary efficacy endpoint that includes time to first occurrence of CV death, nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization for unstable angina, or coronary revascularization. IRB Number 17-108


This trial is sponsored by Esperion Therapeutics, Inc..

Providers Associated With This Trial

Principle Investigator

Sub Investigators

This link will open in a new tab or window.